Contineum Therapeutics

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology, and fibrotic disease. The company was incorporated in 2009 as Pipeline Therapeutics and renamed Contineum Therapeutics in November 2023 to reflect its expansion into fibrotic indications, and is based in San Diego, California. Its two clinical programs target de-risked mechanisms with existing human data: PIPE-791, an LPA1 receptor antagonist being developed in idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 muscarinic receptor antagonist licensed to Johnson & Johnson as JNJ-5120 and in development for major depressive disorder and remyelination in multiple sclerosis. Contineum listed on Nasdaq in April 2024 and carries a substantial cash balance relative to its operating burn, which leaves the equity sensitive to clinical readouts on its partnered and wholly owned programs rather than to near-term financing risk.